Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Genomic landscape of ERBB3 alterations in metastatic solid tumours: a real-world data analysis

Background Although human epidermal growth factor receptor 2 (ERBB2/HER2) is a validated therapeutic target, the significance of ERBB3 (HER3) alterations across solid tumours remains poorly defined. We characterised such alterations to clarify the genomic landscape relevant to HER3-directed strategies, distinguishing s...

M. Kwon, Y. Go, J. Shin et al. · 0 citations
Review Open access Sep 2026

Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study

Extended follow-up confirms that first-line pembrolizumab plus chemotherapy improves efficacy and maintains a manageable safety profile compared with placebo plus chemotherapy, regardless of PD-L1 status, supporting this combination as a first-line treatment option for locally advanced or metastatic HER2-negative gastr...

S. Rha, L. Wyrwicz, P. Yanez et al. · 1 citation · ⚡1

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.